SCHEMBL4001970

SCHEMBL4001970

CCOC(=O)c1cc(S(=O)(=O)N(C)C)c(F)cc1OCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.47
MAPT P10636 1/20 0.47
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
JMJD6 Q6NYC1 1/20 0.39
HTT P42858 2/20 0.39
KMT2A Q03164 1/20 0.38
CYP3A4 P08684 1/20 0.37
ALDH1A1 P00352 4/20 0.36
HSD17B10 Q99714 1/20 0.36
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PKM P14618 1/20 0.36
SREBF1 P36956 1/20 0.35
NR1H3 Q13133 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4006354 0.85 TSHR (0.50) TSHRMAPTCA1CA2CA12
SCHEMBL4004644 0.85 TSHR (0.47) TSHRMAPTCA1CA2CA12
SCHEMBL3997482 0.85 MAPT (0.47) TSHRMAPTCA1CA2CA12
SCHEMBL4001527 0.85 TSHR (0.56) TSHRMAPTCA1CA2CA12
SCHEMBL3997311 0.84 CA1 (0.43) TSHRCA1CA2CA12CA9
SCHEMBL3998773 0.81 MAPT (0.44) TSHRMAPTCA1CA2CA12
SCHEMBL3997692 0.78 MAPT (0.41) TSHRMAPTCA1CA2CA12
SCHEMBL13717090 0.76 KMT2A (0.52) TSHRMAPTKMT2AALDH1A1GAA
SCHEMBL4002658 0.76 TSHR (0.43) TSHRMAPTCA1CA2CA12
SCHEMBL22499513 0.76 GAA (0.42) TSHRHTTKMT2AALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579368-B2 Cis-imidazolines HOFFMAN-LA ROCHE INC. (US) 2009-08-25 US disclosed
EP-1861376-A1 CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS F. Hoffmann-Roche AG (CH) 2007-12-05 EP disclosed
WO-2006097261-A1 CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-21 WO disclosed
US-20060211693-A1 Cis-imidazolines FOTOUHI NADER 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211693-A1 Cis-imidazolines TP53, MDM2, CDC25C TSHR 2239/4885MAPT 3343/4885CA1 2178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.